 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the third quarter ended September 30, 2023. We were pleased to see a 32% increase in...

Acorda Therapeutics Reports Third Quarter 2023 Financial Results

Acorda Therapeutics, Inc. (Nasdaq: ACOR) will host a webcast/conference call in conjunction with its third quarter 2023 update and financial results on Monday, November 13 at 4:30 p.m. ET. To...

Acorda Third Quarter 2023 Update: Webcast/Conference Call Scheduled for November 13, 2023

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Acorda Therapeutics submits new regulatory filings for approval of Inbrija

Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced the submission of new regulatory filings for the approval of INBRIJA (levodopa inhalation powder) in six countries in Latin America by its...

Acorda Therapeutics Announces Biopas Laboratories Submission to Regulatory Agencies in Six Latin American Countries for Approval of INBRIJA

Acorda Therapeutics, Inc. (NASDAQ:ACOR  Get Free Report) was the target of a large growth in short interest in October. As of October 15th, there was short interest totalling 14,600 shares, a...

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Sees Large Increase in Short Interest

StockNews.com started coverage on shares of Acorda Therapeutics (NASDAQ:ACOR  Free Report) in a report published on Thursday morning. The brokerage issued a buy rating on the biopharmaceutical...

Acorda Therapeutics (NASDAQ:ACOR) Research Coverage Started at StockNews.com

Acorda Therapeutics, Inc. (NASDAQ:ACOR  Get Free Report)s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of...

Acorda Therapeutics (NASDAQ:ACOR) Share Price Crosses Above 200 Day Moving Average of $13.34

Acorda Therapeutics, Inc. (NASDAQ:ACOR  Get Free Report)s stock price passed above its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving...

Acorda Therapeutics (NASDAQ:ACOR) Shares Cross Above 200-Day Moving Average of $13.62

Acorda Therapeutics, Inc. (NASDAQ:ACOR Get Free Report) was the target of a significant drop in short interest in the month of August. As of August 15th, there was short interest totalling 12,900 shares, a drop of 21.3% from the July 31st total of 16,400 shares. Based on an average trading volume of...

Acorda Therapeutics, Inc. (NASDAQ:ACOR) Sees Significant Decrease in Short Interest

Unveiling the Intrinsic Value of Acorda TherapeuticsRelated Stocks: ACOR...

Acorda Therapeutics (ACOR): A Comprehensive Analysis of Its Market Value

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its products include Inbrija (levodopa inhalation powder), Ampyra (dalfampridine), Fampyra (fampridine), and Selincro (nalmefene). The firm's also offers Research and Development Programs like ARCUS for acute migraine, Cimaglermin alfa, and rHIgM22. The company was founded by Ronald Cohen in 1995 and is headquartered in New York, NY.

Market Cap	$73.75M
Volume (M)	15,154.00
52-Wk High	$24.20
52-Wk Low	$8.98

Current Price	$12.49
Prev Close	$10.57
Open	$11.36
Dividend Yield	0.00%
50-Day Moving Average	$10.64
Beta	0.80
Avg. Volume	2,908.05
PE Ratio	-0.53

52-Week High	$24.20
52-Week Low	$8.98
Market Capitalization	$73.75M
EPS	-$19.78
Price to Book	0.17
Revenue Per Employee	$910,819.67
Enterprise Value/EBITDA	-142.93

ACOR Acorda Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals